DOCSLIB.ORG

Table 1. Genes Commonly Modulated by Bombesin and DHT Process Official Entrez Classification Symbol Gene Name Gene ID Function Up-Regulated Genes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 1. Genes Commonly Modulated by Bombesin and DHT Process Official Entrez Classification Symbol Gene Name Gene ID Function Up-Regulated Genes Table 1. Genes commonly modulated by Bombesin and DHT Process Official Entrez Classification Symbol Gene Name Gene ID Function Up-regulated Genes androgen-regulated NKX3.11-3, 6 NK3 transcription factor related, 4824 putative tumor suppressor, locus 1 (Drosophila) transcription factor activity TMEPAI2 transmembrane, prostate 56937 negative regulator of cell androgen induced RNA proliferation SARG4 specifically androgen-regulated 79098 unknown protein KLK22-5 kallikrein 2, prostatic 3817 serine protease KLK31-6 kallikrein 3, prostate specific 354 serine protease antigen KLK42,6 kallikrein 4, prostase, enamel 9622 serine protease matrix, prostate TMPRSS22,6 transmembrane, protease, serine 7113 serine protease 2 GREB19 gene regulated by estrogen in 9687 unknown, early response gene breast cancer protein in estrogen receptor regulated pathway angiogenesis JAG11,5 jagged 1 (Alagille syndrome) 182 Notch 1 receptor ligand ADAMTS11,2,4 a disintegrin-like and 9510 anti-angiogenic, involved in metalloprotease (reprolysin type) integrin-mediated signaling with thrombospondin type 1 motif, pathway, negative regulator of 1 proliferation apoptosis THY28 thymocyte protein thy28 29087 may be involved in induction of apoptosis in lymphocytes ISG20L1 interferon stimulated exonuclease 64782 apoptotic nuclease gene 20kDa-like 1 RKHD1 ring finger and KH domain 399664 negative regulator of BCL2 containing 1 expression, proapoptotic cell cycle MPHOSPH9 M-phase phosphoprotein 9 10198 cell cycle regulation TOB2 transducer of ERBB2, 2 10766 negative regulator of cell proliferation cytoskeletal TUBA3 tubulin, alpha 3 7846 microtubule component, microtubule based movement DNA replication ORC5L origin recognition complex, 5001 component of ORC pore subunit 5-like (yeast) complex involved in initiation of DNA replication fatty acid metabolism ELOVL1* elongation of very long chain fatty 64834 fatty acid biosynthesis acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1 ion channel KCNN2 potassium intermediate/small 3781 action potential, calmodulin conductance calcium-activated binding channel, subfamily N, member 2 metabolism HK11 hexokinase 1 3098 glucose metabolism PDIA55 protein disulfide isomerase family 10954 isomerase, electron transporter A, member 5 activity HT008 uncharacterized hypothalamus 55852 phosphoenolpyruvate- protein HT008 dependent sugar phosphotransferase system ADPGK ATP-dependent glucokinase 83440 glucose metabolism protein folding HSPA1A* heat shock 70kDa protein 1A 3303 chaperon protein HSPA1B4 heat shock 70kDa protein 1B 3304 chaperon protein DNAJB15,* DnaJ (Hsp40) homolog, subfamily 3337 chaperon protein B, member 1 DNAJB91 DnaJ (Hsp40) homolog, subfamily 4189 chaperon protein B, member 9 proteinase MMP14 matrix metalloproteinase 14 4323 may be transmembrane instead (membrane-inserted) of secreted, activates MMP2, may be involved in tumor invasion proteolysis CAPN2 calpain 2, (m/II) large subunit 824 protease, calcium activated, nonlysosomal, intracellular cysteine protease signal transduction PDE9A4 phosphodiesterase 9A 5152 hydrolysis of cAMP and cGMP PPFIBP2 PTPRF interacting protein, 8495 unknown function, protein binding protein 2 (liprin beta 2) tyrosine phosphatase interacting EFS embryonal Fyn-associated 10278 SH3 domain containing protein substrate TAX1BP3 Tax1 (human T-cell leukemia 30851 putative wnt/beta-catenin virus type I) binding protein 3 regulatory element IGFBP33 insulin-like growth factor binding 3486 binding protein to IGFI or II, protein 3 negative regulator of signal transduction transcription factor ZBTB165 zinc finger and BTB domain 7704 transcription factor that interacts containing 16 with histone deacetylase MAFB v-maf musculoaponeurotic 9935 bzip transcription factor that fibrosarcoma oncogene homolog represses Ets1 mediated B (avian) transcription in myeloid cells SPDEF6 SAM pointed domain containing 25803 ets transcription factor in ets transcription factor prostate epithelials, androgen independent transactivator of PSA GRHL2 grainyhead-like 2 (Drosophila) 79977 involved in development translation QKI1 quaking homolog, KH domain 9444 RNA binding protein, RNA binding (mouse) translational repressor tumor suppressor FAT FAT tumor suppressor homolog 1 2195 tumor suppressor, member of (Drosophila) cadherin superfamily, may function as adhesion molecule and/or signaling receptor unknown DIPA5 hepatitis delta antigen-interacting 11007 cellular protein that interacts protein A with viral antigen HDAg and can affect HDV DERL2 derlin-2 51009 protein degradation of misfolded ER proteins MGC11242 hypothetical protein MGC11242 79170 unknown ANKRD27 ankyrin repeat domain 27 (VPS9 84079 unknown domain) ABHD3 abhydrolase domain containing 3 171586 unknown Down-regulated Genes androgen-regulated AR androgen receptor 367 nuclear hormone receptor, androgen binding, transcription factor cell cycle regulator CCNG21,5,* cyclin G2 901 cell cycle checkpoint protein upregulated during cell cycle arrest DNA replication NAP1L11,* nucleosome assembly protein 1- 4673 positive regulator of like 1 proliferation, modulates nucleosome assembly and chromatin formation ion channel ENSA endosulfine alpha 2029 endogenous ligand for sulfonylurea receptor, regulates potassium channel on pancreatic beta cells, modulate insulin secretion protein sorting GPP34R GPP34-related protein 55204 may regulate Golgi trafficking RNA processing HNRPDL1,* heterogeneous nuclear 9987 RNA binding protein ribonucleoprotein D-like signal transduction PIK3R11 phosphoinositide-3-kinase, 5295 metabolic action of insulin, regulatory subunit, polypeptide 1 regulatory subunit of PI3K (p85 alpha) PRB4 proline-rich protein BstNI 5545 GPCR signaling pathway subfamily 4 SDC45 syndecan 4 (amphiglycan, 6385 intracellular signaling receptor ryudocan) STK3 serine/threonine kinase 3 (STE20 6788 activated by proapoptotic homolog, yeast) agents PIK3R3 phosphoinositide-3-kinase, 8503 metabolic action of insulin, regulatory subunit, polypeptide 3 regulatory subunit of PI3K (p55, gamma) RAB9A5,8,* member of RAS oncogene family 9367 small GTPase mediated signal transduction NUDT41 nudix (nucleoside diphosphate 11163 regulates turnover of linked moiety X)-type motif 4 diphosphoinositol polyphosphates transcription factor NFAT5* nuclear factor of activated T-cells 10725 regulates gene transcription 5, tonicity-responsive during osmotic stress ZNF297B zinc finger protein 297B 23099 putative transcription factor ZNF505 zinc finger protein 505 81931 putative transcription factor translation EIF4EBP1 eukaryotic translation initiation 1978 negative regulation of factor 4E binding protein 1 translational initiation and protein biosynthesis PAIP13,6,7 poly(A) binding protein interacting 10605 poly(A) binding and capping protein 1 protein unknown MAGEA5 melanoma antigen, family A, 5 4104 unknown KIAA02475 KIAA0247 hypothetical protein 9766 unknown FAM13A1 family with sequence similarity 13, 10144 unknown member A1 PAI-RBP1* PAI-1 mRNA-binding protein 26135 unknown DKFZp434L14 hypothetical protein 51313 unknown 2 DKFZp434L142 DDIT4 DNA-damage-inducible transcript 54541 unknown 4 RNF137 ring finger protein 137 55128 unknown C9orf132 C9orf132 399665 unknown Hs. 539655 cDNA DKFZp434D179 AL39015 unknown 7.1 1-9 Additional reference of androgen regulated genes 1 DePrimo SE, et al. (2002) Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biology 3,research0032.1-0032.12 2 Nelson PS, et al. (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. PNAS 99, 11890- 11895 3 Segawa T, et al. (2002) Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 21, 8749-8758 4 Stanbrough M, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen- independent prostate cancer. Cancer Res. 66, 2815-2825 5 Velasco AM, et al, (2004) Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 145, 3913-3924 6 Xu LL, et al. (2001) Quantitative expression profile of androgen regulated genes in prostate cancer cells and identification of prostate specific genes. Int. J. Cancer 92, 322-328 7 York TP, et al. (2005) cDNA microarray analysis identifies genes induced in common by peptide growth factors and androgen in human prostatic epithelial cells. Molecular Carcinogenesis 44, 242-251 8 Masuda K, et al. (2005) Androgen receptor binding sites identified by a GREF_GATA model. J. Mol. Biol. 353, 763-771 9 Rae JM, et al. (2006) GREB1 is a novel androgen-regulated gene required for prostate cancer growth. Prostate 66, 886-894 * Genes regulated by MYC Zeller KI, et al. (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biology 4, R69.1-R69.10 .
Load more

Recommended publications
  • Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
    G C A T T A C G G C A T genes Review Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling Aoife A. Nolan 1, Nourhan K. Aboud 1, Walter Kolch 1,2,* and David Matallanas 1,* 1 Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland; [email protected] (A.A.N.); [email protected] (N.K.A.) 2 Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland * Correspondence: [email protected] (W.K.); [email protected] (D.M.) Abstract: Oncogenic RAS (Rat sarcoma) mutations drive more than half of human cancers, and RAS inhibition is the holy grail of oncology. Thirty years of relentless efforts and harsh disappointments have taught us about the intricacies of oncogenic RAS signalling that allow us to now get a pharma- cological grip on this elusive protein. The inhibition of effector pathways, such as the RAF-MEK-ERK pathway, has largely proven disappointing. Thus far, most of these efforts were aimed at blocking the activation of ERK. Here, we discuss RAF-dependent pathways that are regulated through RAF functions independent of catalytic activity and their potential role as targets to block oncogenic RAS signalling. We focus on the now well documented roles of RAF kinase-independent functions in apoptosis, cell cycle progression and cell migration. Keywords: RAF kinase-independent; RAS; MST2; ASK; PLK; RHO-α; apoptosis; cell cycle; cancer therapy Citation: Nolan, A.A.; Aboud, N.K.; Kolch, W.; Matallanas, D. Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling.
    [Show full text]
  • Phospho-RAF1(S43) Antibody Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap3332a
    9765 Clairemont Mesa Blvd, Suite C San Diego, CA 92124 Tel: 858.875.1900 Fax: 858.622.0609 Phospho-RAF1(S43) Antibody Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP3332a Specification Phospho-RAF1(S43) Antibody - Product Information Application DB,E Primary Accession P04049 Other Accession P11345, Q99N57, A7E3S4 Reactivity Human Predicted Bovine, Mouse, Rat Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Clone Names RB11127 Calculated MW 73052 Phospho-RAF1(S43) Antibody - Additional Information Gene ID 5894 Dot blot analysis of Phospho-RAF1-S43 Phospho-specific Pab (Cat.AP3332a) on Other Names nitrocellulose membrane. 50ng of RAF proto-oncogene serine/threonine-protein Phospho-peptide or Non Phospho-peptide per kinase, Proto-oncogene c-RAF, cRaf, Raf-1, dot were adsorbed. Antobodies working RAF1, RAF concentration was 0.5ug per ml. Target/Specificity This RAF1 Antibody is generated from rabbits Phospho-RAF1(S43) Antibody - immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid Background residues surrounding S43 of human RAF1. Raf-1 is a MAP kinase kinase kinase (MAP3K) Dilution which functions downstream of the Ras family of DB~~1:500 membrane associated GTPases to which it binds directly. Once activated Raf-1 can phosphorylate Format to activate the dual specificity protein kinases Purified polyclonal antibody supplied in PBS MEK1 and MEK2 which in turn phosphorylate to with 0.09% (W/V) sodium azide. This antibody activate the serine/threonine specific protein is purified through a protein A column, kinases ERK1 and ERK2. Activated ERKs are followed by peptide affinity purification. pleiotropic effectors of cell physiology and play an important role in the control of gene Storage expression involved in the cell division cycle, Maintain refrigerated at 2-8°C for up to 6 apoptosis, cell differentiation and cell migration.
    [Show full text]
  • Machine-Learning and Chemicogenomics Approach Defi Nes and Predicts Cross-Talk of Hippo and MAPK Pathways
    Published OnlineFirst November 18, 2020; DOI: 10.1158/2159-8290.CD-20-0706 RESEARCH ARTICLE Machine -Learning and Chemicogenomics Approach Defi nes and Predicts Cross-Talk of Hippo and MAPK Pathways Trang H. Pham 1 , Thijs J. Hagenbeek 1 , Ho-June Lee 1 , Jason Li 2 , Christopher M. Rose 3 , Eva Lin 1 , Mamie Yu 1 , Scott E. Martin1 , Robert Piskol 2 , Jennifer A. Lacap 4 , Deepak Sampath 4 , Victoria C. Pham 3 , Zora Modrusan 5 , Jennie R. Lill3 , Christiaan Klijn 2 , Shiva Malek 1 , Matthew T. Chang 2 , and Anwesha Dey 1 ABSTRACT Hippo pathway dysregulation occurs in multiple cancers through genetic and non- genetic alterations, resulting in translocation of YAP to the nucleus and activation of the TEAD family of transcription factors. Unlike other oncogenic pathways such as RAS, defi ning tumors that are Hippo pathway–dependent is far more complex due to the lack of hotspot genetic alterations. Here, we developed a machine-learning framework to identify a robust, cancer type–agnostic gene expression signature to quantitate Hippo pathway activity and cross-talk as well as predict YAP/TEAD dependency across cancers. Further, through chemical genetic interaction screens and multiomics analyses, we discover a direct interaction between MAPK signaling and TEAD stability such that knockdown of YAP combined with MEK inhibition results in robust inhibition of tumor cell growth in Hippo dysregulated tumors. This multifaceted approach underscores how computational models combined with experimental studies can inform precision medicine approaches including predictive diagnostics and combination strategies. SIGNIFICANCE: An integrated chemicogenomics strategy was developed to identify a lineage- independent signature for the Hippo pathway in cancers.
    [Show full text]
  • C-RAF (Phospho-Tyr341) Antibody
    Product Datasheet C-RAF (Phospho-Tyr341) Antibody Catalog No: #11668 Package Size: #11668-1 50ul #11668-2 100ul Orders: [email protected] Support: [email protected] Description Product Name C-RAF (Phospho-Tyr341) Antibody Host Species Rabbit Clonality Polyclonal Purification Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide. Applications WB IHC Species Reactivity Hu Specificity The antibody detects endogenous levels of Raf1 only when phosphorylated at tyrosine 341. Immunogen Type Peptide-KLH Immunogen Description Peptide sequence around phosphorylation site of tyrosine 341 (S-Y-Y(p)-W-E) derived from Human C-RAF . Target Name C-RAF Modification Phospho Other Names C-RAF; C-Raf; CRAF; RAF-1; Accession No. Swiss-Prot#: P04049; NCBI Gene#: 5894; NCBI Protein#: NP_002871.1. SDS-PAGE MW 74kd Concentration 1.0mg/ml Formulation Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Storage Store at -20°C/1 year Application Details Western blotting: 1:500~1:1000 Immunohistochemistry: 1:50~1:100 Images Western blot analysis of extracts from Jurkat cells treated with Paclitaxel using Raf1 (Phospho-Tyr341) Antibody #11668.The lane on the right is treated with the antigen-specific peptide. Address: 8400 Baltimore Ave., Suite 302, College Park, MD 20740, USA http://www.sabbiotech.com 1 Immunohistochemical analysis of paraffin-embedded human pancreas tissue using Raf1 (Phospho-Tyr341) antibody #11668 (left)or the same antibody preincubated with blocking peptide (right).
    [Show full text]
  • Egfrviii and Pten Deletion Mutations Influence Genotype-Dependent Kinome Activation
    EGFRvIII and Pten Deletion Mutations Influence Genotype-Dependent Kinome Activation in Immortalized Murine Astrocyte Models of Glioblastoma Madison Butler C. Ryan Miller Lab Abstract Glioblastoma (GBM) is the most common malignant primary brain tumor. Receptor tyrosine kinase (RTK) pathways are frequently mutated in GBM, including alterations in the RTK Epidermal Growth Factor Receptor (EGFR). Moreover, EGFR variant III (EGFRvIII) is the most common activating mutation in GBM. Given its frequency, specificity, and role in promoting gliomagenesis, EGFR dysfunction is a prime target for drug treatment. However, multiple resistance mechanisms, such as co-occurrence of EGFRvIII and deletion of the tumor suppressor PTEN, prevent effective treatment via activation of alternate kinase pathways. To observe the differential kinase activation involved in EGFRvIII- and PTEN loss- driven gliomagenesis and identify potential kinase targets for dual therapy, we examined immortalized murine astrocytes derived from non-germline genetically engineered mouse models expressing four core genotypes: wild-type EGFR + wild- type Pten (C), wild-type EGFR + Pten deletion (CP), EGFRvIII + wild-type Pten (CEv3), and EGFRvIII + Pten deletion (CEv3P). We used RNA sequencing and multiplexed inhibitor bead affinity chromatography and mass spectrometry (MIB-MS) to determine the baseline transcriptomes and kinomes of each genotype. We determined that cell lines exhibited genotype- dependent baseline RNA expression and kinase activity as a result of EGFRvIII and/or Pten deletion relative to C astrocytes and across genotypes. We observed several differentially- activated kinases that represent potential targets for dual treatment with EGFR TKI. We are currently examining changes in the kinome profile of each cell line after both acute and chronic treatment with tyrosine kinase inhibitors (TKI).
    [Show full text]
  • Common and Distinctive Functions of the Hippo Effectors Taz and Yap In
    TISSUE-SPECIFIC STEM CELLS aRandall Division of Cell and Common and Distinctive Functions of the Hippo Molecular Biophysics, King’s College London, London, UK; Effectors Taz and Yap in Skeletal Muscle Stem Cell bSchool of Medicine, Medical Sciences & Nutrition, Function University of Aberdeen, Foresterhill, Aberdeen, a b b a Scotland, UK; cSystems CONGSHAN SUN, VANESSA DE MELLO, ABDALLA MOHAMED, HUASCAR P. O RTUSTE QUIROGA, c b d,e,f Biology Ireland, Conway AMAYA GARCIA-MUNOZ, ABDULLAH AL BLOSHI, ANNIE M. TREMBLAY, c g b c Institute, Dublin, Ireland; ALEXANDER VON KRIEGSHEIM, ELAINA COLLIE-DUGUID, NEIL VARGESSON, DAVID MATALLANAS, d b,h a Stem Cell Program, HENNING WACKERHAGE, PETER S. ZAMMIT Children’s Hospital, Boston, Massachusetts, USA; Key Words. Taz • Yap • Tead • Satellite cells • Muscle stem cells eDepartment of Stem Cell and Regenerative Biology, Harvard University, ABSTRACT Cambridge, Massachusetts, USA; fHarvard Stem Cell Hippo pathway downstream effectors Yap and Taz play key roles in cell proliferation and regen- Institute, Cambridge, eration, regulating gene expression especially via Tead transcription factors. To investigate their Massachusetts, USA; gCentre role in skeletal muscle stem cells, we analyzed Taz in vivo and ex vivo in comparison with Yap. for Genome Enabled Biology Small interfering RNA knockdown or retroviral-mediated expression of wild-type human or con- and Medicine, School of stitutively active TAZ mutants in satellite cells showed that TAZ promoted proliferation, a func- Medicine, Medical Sciences tion shared with YAP. However, at later stages of myogenesis, TAZ also enhanced myogenic and Nutrition, University of differentiation of myoblasts, whereas YAP inhibits such differentiation. Functionally, while mus- Aberdeen, Foresterhill, cle growth was mildly affected in Taz (gene Wwtr1–/–) knockout mice, there were no overt Aberdeen, Scotland, UK; effects on regeneration.
    [Show full text]
  • Nursing Genetic Research: New Insights Linking Breast Cancer Genetics and Bone Density
    healthcare Concept Paper Nursing Genetic Research: New Insights Linking Breast Cancer Genetics and Bone Density 1, 2, 3, Antonio Sanchez-Fernandez y, Raúl Roncero-Martin y, Jose M. Moran * , Jesus Lavado-García 2 , Luis Manuel Puerto-Parejo 2 , Fidel Lopez-Espuela 2, Ignacio Aliaga 3 and María Pedrera-Canal 2 1 Servicio de Tocoginecología, Complejo Hospitalario de Cáceres, 10004 Cáceres, Spain; [email protected] 2 Metabolic Bone Diseases Research Group, Nursing Department, Nursing and Occupational Therapy College, University of Extremadura, Avd. Universidad s/n, 10003 Cáceres, Spain; [email protected] (R.R.-M.); [email protected] (J.L.-G.); [email protected] (L.M.P.-P.); fi[email protected] (F.L.-E.); [email protected] (M.P.-C.) 3 Departamento de Estomatología II, Universidad Complutense de Madrid, 28040 Madrid, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-927-257450 Both authors contributed equally to this work. y Received: 25 April 2020; Accepted: 11 June 2020; Published: 15 June 2020 Abstract: Nursing research is expected to provide options for the primary prevention of disease and health promotion, regardless of pathology or disease. Nurses have the skills to develop and lead research that addresses the relationship between genetic factors and health. Increasing genetic knowledge and research capacity through interdisciplinary cooperation as well as the development of research resources, will accelerate the rate at which nurses contribute to the knowledge about genetics and health. There are currently different fields in which knowledge can be expanded by research developed from the nursing field. Here, we present an emerging field of research in which it is hypothesized that genetics may affect bone metabolism.
    [Show full text]
  • Anti-LATS1 / WARTS Antibody (ARG43046)
    Product datasheet [email protected] ARG43046 Package: 50 μg anti-LATS1 / WARTS antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes LATS1 / WARTS Tested Reactivity Hu Tested Application FACS, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name LATS1 / WARTS Antigen Species Human Immunogen Recombinant protein corresponding to Q637-A698 of Human LATS1 / WARTS. Conjugation Un-conjugated Alternate Names wts; Serine/threonine-protein kinase LATS1; WARTS; WARTS protein kinase; h-warts; EC 2.7.11.1; Large tumor suppressor homolog 1 Application Instructions Application table Application Dilution FACS 1:150 - 1:500 IHC-P 1:200 - 1:1000 WB 1:500 - 1:2000 Application Note IHC-P: Antigen Retrieval: Heat mediation was performed in Citrate buffer (pH 6.0) for 20 min. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 127 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.2% Na2HPO4, 0.9% NaCl, 0.05% Sodium azide and 4% Trehalose. Preservative 0.05% Sodium azide Stabilizer 4% Trehalose Concentration 0.5 - 1 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed www.arigobio.com 1/3 before use. Note For laboratory research only, not for drug, diagnostic or other use.
    [Show full text]
  • STK3 Active (S6573)
    STK3 Active human, recombinant GST-tagged, expressed in Sf9 cells Catalog Number S6573 Lot Number 019K1598 Storage Temperature –70 °C Synonyms: KRS1; MST2 Figure 1. SDS-PAGE Gel of Lot Number 019K1598: Product Description >80% (densitometry) STK3, also known as MST2, encodes a protein of 491 amino acids which contains an N-terminal catalytic 170 1 130 domain characteristic of STKs. STK3 and STK4 share 100 STK3 94% amino acid identity in the catalytic domain and 72 78% identity overall. RAF1 has been shown to counteract apoptosis by suppressing the activation of 55 mammalian sterile 20-like kinase (MST2). STK3 is a 40 kinase that is activated by the proapoptotic agents, 33 straurosporine and FAS ligand.2 STK3 activation presumably allows cells to resist unfavorable environmental conditions. Figure 2. This recombinant product was expressed by Specific Activity of Lot Number 019K1598: baculovirus in Sf9 insect cells using an N-terminal 277 nmole/min/mg GST-tag. The gene accession number is BC 010640. It is supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM 500,000 NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol. 400,000 300,000 Molecular mass: ~87 kDa ctivity (cpm) 200,000 A 100,000 Purity: ³70% (SDS-PAGE, see Figure 1) 0 0 40 80 120 160 Specific Activity: 235–319 nmole/min/mg (see Figure 2) Protein (ng) Precautions and Disclaimer This product is for R&D use only, not for drug, Procedure household, or other uses. Please consult the Material Preparation Instructions Safety Data Sheet for information regarding hazards Kinase Assay Buffer – 25 mM MOPS, pH 7.2, 12.5 mM and safe handling practices.
    [Show full text]
  • STK3 Suppresses Ovarian Cancer Progression by Activating NF-Κb Signaling to Recruit CD8+ T-Cells
    Hindawi Journal of Immunology Research Volume 2020, Article ID 7263602, 17 pages https://doi.org/10.1155/2020/7263602 Research Article STK3 Suppresses Ovarian Cancer Progression by Activating NF-κB Signaling to Recruit CD8+ T-Cells Xiangyu Wang ,1,2 Fengmian Wang,1,2 Zhi-Gang Zhang ,3 Xiao-Mei Yang ,3 and Rong Zhang 1,2 1The Third School of Clinical Medicine, Southern Medical University, Guangzhou 510500, China 2Department of Obstetrics and Gynecology, Fengxian Central Hospital Affiliated to the Southern Medical University, Shanghai 201499, China 3State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201109, China Correspondence should be addressed to Xiao-Mei Yang; [email protected] and Rong Zhang; [email protected] Received 6 July 2020; Revised 11 August 2020; Accepted 26 August 2020; Published 29 September 2020 Academic Editor: Jian Song Copyright © 2020 Xiangyu Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Serine/threonine protein kinase-3 (STK3) is a critical molecule of the Hippo pathway but little is known about its biological functions in the ovarian cancer development. We demonstrated the roles of STK3 in ovarian cancer. Existing databases were used to study the expression profile of STK3. STK3 was significantly downregulated in OC patients, and the low STK3 expression was correlated with a poor prognosis. In vitro cell proliferation, apoptosis, and migration assays, and in vivo subcutaneous xenograft tumor models were used to determine the roles of STK3.
    [Show full text]
  • A YAP/TAZ-Induced Feedback Mechanism Regulates Hippo Pathway Homeostasis
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis Toshiro Moroishi,1 Hyun Woo Park,1 Baodong Qin,1,2 Qian Chen,3 Zhipeng Meng,1 Steven W. Plouffe,1 Koji Taniguchi,4,5 Fa-Xing Yu,6,7 Michael Karin,4,5 Duojia Pan,3 and Kun-Liang Guan1 1Department of Pharmacology, Moores Cancer Center, University of California at San Diego, La Jolla, California 92093, USA; 2Department of Laboratory Medicine, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, China; 3Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA; 4Department of Pharmacology, 5Department of Pathology, University of California at San Diego, La Jolla, California 92093, USA; 6Children’s Hospital, 7Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) are major downstream effectors of the Hippo pathway that influences tissue homeostasis, organ size, and cancer development. Aberrant hyperactivation of YAP/TAZ causes tissue overgrowth and tumorigenesis, whereas their inactivation impairs tissue development and regeneration. Dynamic and precise control of YAP/TAZ activity is thus important to ensure proper physiological regulation and homeostasis of the cells. Here, we show that YAP/TAZ activation results in activation of their negative regulators, LATS1/2 (large tumor suppressor 1/2) kinases, to constitute a negative feedback loop of the Hippo pathway in both cultured cells and mouse tissues. YAP/TAZ in complex with the transcription factor TEAD (TEA domain family member) directly induce LATS2 expression.
    [Show full text]
  • Greb1is a Novel Androgen-Regulated Gene Required for Prostate Cancer Growth
    The Prostate GREB1is a Novel Androgen-Regulated Gene Required for Prostate Cancer Growth James M. Rae,1* Michael D. Johnson,2 Kevin E. Cordero,1 Joshua O. Scheys,1 Jose´ M. Larios,1 Marco M. Gottardis,3 Kenneth J. Pienta,1 and Marc E. Lippman1 1Division of Hematology Oncology,Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor,Michigan 2Department of Oncology,Georgetown University,Washington, District of Columbia 3Department of Discovery Biology,Bristol^ Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey BACKGROUND. Gene regulated in breast cancer 1 (GREB1) is a novel estrogen-regulated gene shown to play a pivotal role in hormone-stimulated breast cancer growth. GREB1 is expressed in the prostate and its putative promoter contains potential androgen receptor (AR) response elements. METHODS. We investigated the effects of androgens on GREB1 expression and its role in androgen-dependent prostate cancer growth. RESULTS. Real-time PCR demonstrated high level GREB1 expression in benign prostatic hypertrophy (BPH), localized prostate cancer (L-PCa), and hormone refractory prostate cancer (HR-PCa). Androgen treatment of AR-positive prostate cancer cells induced dose-dependent GREB1 expression, which was blocked by anti-androgens. AR binding to the GREB1 promoter was confirmed by chromatin immunoprecipitation (ChIP) assays. Suppression of GREB1 by RNA interference blocked androgen-stimulated LNCaP cell proliferation. CONCLUSIONS. GREB1 is expressed in proliferating prostatic tissue and prostate
    [Show full text]